Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf T-cell immunotherapies targeting infectious diseases and oncology indications. The company reached public markets through a SPAC transaction and filed its quarterly Form 10-Q with the SEC on May 17, 2022, reflecting its status as an active public reporting entity in the biotechnology and life sciences sector. Tevogen Bio's pipeline centers on proprietary antigen-specific T-cell therapies engineered for broad patient applicability. To explore the complete filing history, SPAC transaction details, and sponsor data for TVGN, sign up for full access on SpacDesk.